性传播感染(STIs)对全世界的性健康和生殖健康产生了深远的影响。梅毒,淋病,衣原体,滴虫病是目前可治愈的四种性传播感染。然而,大多数性传播感染病例无症状,未经实验室诊断未发现.乙型肝炎病毒,单纯疱疹病毒,人类免疫缺陷病毒(HIV),人乳头瘤病毒(HPV)是四种病毒和无法治愈的感染,但是可以通过治疗来缓解。我们调查了马普托女性中某些性传播病原体的患病率及其与HPV和HIV感染的关系。莫桑比克首都。在马普托的马瓦兰卫生机构,对233名寻求与妇科症状有关的保健的非孕妇进行了横断面研究,在2018年2月1日至2019年7月30日之间。收集宫颈刷样品并提取DNA。通过手动Hybrispot平台(体外,诊断大师,塞维利亚,西班牙)。使用快速测试进行HIV测试:确定HIV1/2测试(AlereAbbott实验室,东京,日本)进行筛选,和UniGoldHIV(三位一体生物技术,爱尔兰)进行确认。所有女性(n=233)均为杜氏嗜血杆菌和单纯疱疹病毒1(HSV-1)阴性。在233名女性中,发现性传播感染的患病率很高(89%),63%的女性HPV阳性,24%的女性HIV阳性。梅毒螺旋体(TP),阴道毛滴虫(电视),单纯疱疹病毒2型(HSV-2),沙眼衣原体(CT)检测占17%,14%,8%,8%的女性,分别。作为一种常见的现象,阴道分泌物(90%)是大多数女性报告的下生殖道症状.在56%(130/233)中检测到与任何STI和HPV的共感染,而45%(59/130)的共感染是高风险HPV(hrHPV)基因型。在HPV阳性参与者中,TP感染最普遍(27%)。总的来说,28%(66/233)的参与者对任何hrHPV基因型均为阳性。在15%(34/233)的研究参与者中发现了与任何STI和HIV的共感染。HPV感染与TP(p=0.039)和HSV-2(p=0.005)之间存在显着关联。电视,TP,和CT-S1-CT-S2阳性在HIV阳性参与者中明显更为普遍.原虫解脲脲原体/细小支原体和人型支原体分别检出84.0%(195/233)和45%(105/233),分别。本研究描述了性传播感染的高患病率。在大多数研究受试者中发现了HPV和性传播感染之间的共感染。HPV的高患病率强调需要HPV疫苗接种以预防该人群中的宫颈癌。性传播感染的管理对于出现妇科症状的妇女也很重要。
Sexually transmitted infections (STIs) have a profound impact on sexual and reproductive health worldwide. Syphilis, gonorrhea, chlamydia, and trichomoniasis are four currently curable STIs. However, most STI cases are asymptomatic and not detected without laboratory diagnostics. Hepatitis B virus, herpes simplex virus, human immunodeficiency virus (HIV), and human papillomavirus (HPV) are four viral and incurable infections, but they can be mitigated by treatment. We investigated the prevalence of selected sexually transmitted pathogens and their relationship with HPV and HIV infection in women from Maputo, the capital of Mozambique. A cross-sectional study was conducted on 233 non-pregnant women seeking health care relating to gynecological symptoms in Mavalane Health facilities in Maputo, between the 1st of February 2018 and the 30th of July 2019. Cervical brush samples were collected and DNA was extracted. Selected STIs including HPV were detected using multiplex STD and HPV Direct Flow Chip Kits through a manual Hybrispot platform (Vitro, Master Diagnostica, Sevilla, Spain). HIV testing was performed using rapid tests: Determine HIV 1/2 test (Alere Abbott Laboratories, Tokyo, Japan) for screening, and UniGold HIV (Trinity Biotech, Ireland) for confirmation. All women (n = 233) were negative for Haemophilus ducreyi and Herpes Simplex Virus-1 (HSV-1). Among the 233 women, a high prevalence of STIs was found (89%), 63% of the women were positive for HPV and 24% were HIV positive. Treponema pallidum (TP), Trichomonas vaginalis (TV), Herpes Simplex Virus-2 (HSV-2), and Chlamydia trachomatis (CT) were detected in 17%, 14%, 8%, and 8% of the women, respectively. As a common phenomenon, vaginal discharge (90%) was the lower genital tract symptom reported by the majority of the women. Co-infection with any STI and HPV was detected in 56% (130/233) while 45% (59/130) of the co-infections were with high-risk HPV (hrHPV) genotypes. Among the HPV-positive participants, infection by TP was the most prevalent (27%). In total, 28% (66/233) of the participants were positive for any hrHPV genotypes. Co-infection with any STI and HIV was found in 15% (34/233) of the study participants. There was a significant association between HPV infection and TP (p = 0.039) and HSV-2 (p = 0.005). TV, TP, and CT-S1-CT-S2 positivity were significantly more prevalent in HIV-positive participants. Pathobionts Ureaplasma urealyticum/parvum and Mycoplasma hominis were detected in 84.0% (195/233) and 45% (105/233), respectively. This present study describes a high prevalence of STIs. Co-infection between HPV and STIs was found in the majority of the study subjects. The high prevalence of HPV emphasizes the need for HPV vaccination to prevent cervical cancer in this population. Management of STIs is also important in women presenting with gynecological symptoms.